Published in Clin Infect Dis on November 01, 2011
Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis (2014) 4.09
Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother (2012) 3.12
Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med (2013) 2.46
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother (2012) 1.30
Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol (2012) 1.17
Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis (2011) 1.16
KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother (2014) 1.14
Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J (2015) 1.13
In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia. PLoS One (2013) 1.06
Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob Agents Chemother (2013) 1.06
Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis (2013) 1.03
Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. Antimicrob Agents Chemother (2014) 1.00
Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013. Malar J (2014) 0.96
Malaria ecology along the Thailand-Myanmar border. Malar J (2015) 0.96
Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J (2014) 0.95
Microsatellite genotyping of Plasmodium vivax infections and their relapses in pregnant and non-pregnant patients on the Thai-Myanmar border. Malar J (2013) 0.93
Longitudinal in vitro surveillance of Plasmodium falciparum sensitivity to common anti-malarials in Thailand between 1994 and 2010. Malar J (2012) 0.91
Artemisinin-naphthoquine combination versus chloroquine-primaquine to treat vivax malaria: an open-label randomized and non-inferiority trial in Yunnan Province, China. Malar J (2013) 0.90
Methylene blue inhibits the asexual development of vivax malaria parasites from a region of increasing chloroquine resistance. J Antimicrob Chemother (2014) 0.90
Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther (2016) 0.88
Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrob Agents Chemother (2015) 0.84
Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand. CPT Pharmacometrics Syst Pharmacol (2014) 0.84
Tackling the malaria problem in the South-East Asia Region: need for a change in policy? Indian J Med Res (2013) 0.82
Chloroquine remains effective for treating Plasmodium vivax malaria in Pursat province, Western Cambodia. Antimicrob Agents Chemother (2014) 0.82
Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India. PLoS One (2016) 0.81
Slow clearance of Plasmodium vivax with chloroquine amongst children younger than six months of age in the Brazilian Amazon. Mem Inst Oswaldo Cruz (2014) 0.80
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies. PLoS One (2013) 0.79
Malaria in the post-partum period; a prospective cohort study. PLoS One (2013) 0.78
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med (2015) 0.78
Plasmodium vivax Malaria in Cambodia. Am J Trop Med Hyg (2016) 0.77
A Randomized Comparison of Chloroquine Versus Dihydroartemisinin-Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam. Am J Trop Med Hyg (2016) 0.75
The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet (2007) 4.85
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother (2004) 4.54
Plasmodium vivax resistance to chloroquine? Lancet (1989) 4.51
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
The assessment of antimalarial drug efficacy. Trends Parasitol (2002) 3.38
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis (2007) 3.27
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS One (2007) 2.66
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg (2003) 2.49
Chloroquine-resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis (2007) 2.43
STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. VI. THE PHYSIOLOGICAL DISPOSITION, ANTIMALARIAL ACTIVITY, AND TOXICITY OF SEVERAL DERIVATIVES OF 4-AMINOQUINOLINE. J Clin Invest (1948) 2.31
Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg (1995) 2.30
Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg (2000) 2.10
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J (2008) 1.91
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health (2008) 1.85
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol (2004) 1.84
Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg (2009) 1.57
Plasmodium vivax trophozoites insensitive to chloroquine. Malar J (2008) 1.54
Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol (2004) 1.20
A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J Pharm Biomed Anal (2005) 1.09
Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar J (2011) 1.08
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (2005) 12.98
Typhoid fever. N Engl J Med (2002) 12.96
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis (2007) 10.66
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 8.73
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
The pathophysiology of vivax malaria. Trends Parasitol (2009) 4.57
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health (2006) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J (2008) 4.33
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med (2006) 3.83
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One (2013) 3.66
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med (2005) 3.15
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Artemisinin combination therapy for vivax malaria. Lancet Infect Dis (2010) 3.08
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J Infect Dis (2007) 3.02
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis (2008) 3.01
Recurrent gene amplification and soft selective sweeps during evolution of multidrug resistance in malaria parasites. Mol Biol Evol (2006) 3.01
How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health (2005) 2.95
On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J Infect Dis (2010) 2.91
Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol (2009) 2.85
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Antimalarial drug toxicity: a review. Drug Saf (2004) 2.76